TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: <100nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: 550nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1(Homo sapiens (Human))
Ironwood Pharmaceuticals
US Patent
Ironwood Pharmaceuticals
US Patent
Affinity DataEC50: >1.00E+3nMAssay Description:Human embryonic kidney cells (HEK293), endogenously expressing soluble guanylate cyclase (sGC), were used to evaluate the activity of test compounds....More data for this Ligand-Target Pair